Meeting
2019 ASCO Annual Meeting
Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.
Authors
Edward B. Garon
David Geffen School of Medicine, University of California/TRIO-US Network, Los Angeles, CA
Edward B. Garon , Byoung Chul Cho , Niels Reinmuth , Ki Hyeong Lee , Alexander Luft , Myung-Ju Ahn , Gilles Robinet , Sylvestre Le Moulec , Ronald Natale , Jeffrey Gary Schneider , Frances A. Shepherd , Marina Chiara Garassino , Sarayut Lucien Geater , Zsolt Papai-Szekely , Tran Van Ngoc , Feng Liu , Urban J. Scheuring , Anna Rydén , Solange Peters , Naiyer A. Rizvi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02453282
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9048)
DOI
10.1200/JCO.2019.37.15_suppl.9048
Abstract #
9048
Poster Bd #
371
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck
Poster
2022 ASCO Annual Meeting
Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.
First Author: Byoung Chul Cho
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal